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Introduction
The first external insulin pump device to deliver 
continuous subcutaneous insulin infusion (CSII or “insulin 
pump”) therapy was used more than 30 years ago. 
Subsequently, the Diabetes Control and Complications 
Trial (DCCT) has convincingly demonstrated that 
stricter glycaemic control, using insulin delivered by 
multiple-dose injections (MDI) or CSII, prevents and 
retards the progression of microvascular complications. 
Technological improvements in pump design and 
functionality, the wider dissemination of accumulated 
knowledge and the desire to achieve blood glucose 
values as close to the normal range as possible, have 
resulted in a significant increase in insulin pump use 
throughout the world. An increasing body of evidence 
supports the ability of insulin pump therapy to improve 
glycaemic control while reducing hypoglycaemic 
episodes when used in appropriately selected patients 
with type 1 diabetes.
The local use of insulin pumps has expanded 
significantly since its reintroduction into South Africa in 
2001, and it can no longer be ignored as a therapeutic 
option for selected patients with type 1 diabetes 
in this country. However, if CSII is to be a viable and 
sustainable therapeutic alternative in appropriate 
patients, a balance needs to be struck between 
CSII use and the ability of the healthcare network to 
support the additional costs. The benefits of CSII should 
be measurable and demonstrable. Creation of an 
environment in which these benefits can be realised 
will ensure the viability and sustainability of this form of 
therapy in the diabetes care armamentarium. 
In order to obtain the maximum and expected benefits 
from CSII therapy, the Society for Endocrinology, 
Metabolism and Diabetes of South Africa (SEMDSA), 
Paediatric and Adolescent Endocrinology and 
Diabetes Society of South Africa (PAEDS-SA) and the 
Centre for Diabetes and Endocrinology (CDE) have 
collaborated, under the banner of the Association of 
Clinical Endocrinologists of South Africa (ACE-SA), to 
issue guidelines on CSII in South Africa. 
The role of ACE-SA will be to: 
• Co-ordinate the training and continuing medical 
education for new and established CSII facilities.
• Establish and co-ordinate the CSII training for 
registrars and fellows seeking certification in 
Endocrinology and Metabolism.
• Establish a voluntary database of CSII users in South 
Africa, and to review this data to critically analyse 
the impact of CSII therapy. 
• Publish and review CSII guidelines, and make 
recommendations for the recognition of CSII 
providers.
Insulin pump technology
The insulin pump is a small, pager-sized portable device, 
with a refillable storage reservoir for insulin, connected 
to the body by means of a thin tube attached to a 
subcutaneously inserted cannula. The cannula usually 
needs replacing every 2-3 days. The pump can 
be programmed to deliver insulin at variable rates 
throughout the day. 
There are two main types of programmable insulin 
delivery:
•	 Basal	 rate	 insulin	 supplied	 continuously: A single, 
basal insulin rate can be planned and pre-
programmed for the entire day (24 hours), or the 
basal rate can be varied for different times of the 
day, e.g. based on changing requirements during 
the day and at night.
•	 Bolus	insulin: Here, a higher insulin dose is given with 
the press of a button, either as a single bolus, or 
infused over a short period at meal times. It can also 
be used to correct high blood glucose levels.
Continuous subcutaneous insulin infusion therapy  
in type 1 diabetes: 2013 clinical guidelines and  
recommendations from the Association of Clinical 
Endocrinologists of South Africa (ACE-SA)
A Amod, M Carrihill, JA Dave, LA Distiller, W May, I Paruk, FJ Pirie, D Segal
Association of Clincial Endocrinologists of South Africa (ACE-SA)
 Peer reviewed. (Submitted: 2013-01-14. Accepted: 2013-02-11.) © SEMDSA JEMDSA 2013;18(1):15-19
Guidelines: Continuous subcutaneous insulin infusion pump therapy in type 1 diabetes
16 2013 Volume 18 No 1JEMDSA
Insulin pumps can deliver insulin more consistently 
and precisely than pen devices and syringes. Dose 
adjustments as small as 0.05 units are possible with 
some pump models, and this can be particularly useful 
when dealing with smaller children.  
Advantages of continuous subcutaneous insulin 
infusion
CSII enables users to lead a flexible and spontaneous 
lifestyle in terms of meal times and physical exercise. It:
• Enhances the flexibility to adjust the insulin dose 
according to food intake.
• Uses only short-acting insulin analogues. As a result, it 
can better mimic physiological insulin secretion and 
ensure continuous insulin availability throughout the 
day (24 hours).
• Enables users to programme and vary the basal 
insulin rate in accordance with varying requirements 
over 24 hours, thus reducing fluctuating blood 
glucose levels and hypoglycaemic episodes.
• Enables users to increase the basal rate during the 
second half of the night, thus overcoming the dawn 
phenomenon and preventing high blood glucose 
values in the morning, without having to endure 
hypoglycaemia during the night.
• Insulin pump therapy can result in improved 
metabolic control in correctly selected patients, 
without increased frequency of severe hypo-
glycaemia that is characteristic of intensive therapy 
by injection.
Disadvantages of continuous subcutaneous 
insulin infusion 
Disadvantages of continuous subcutaneous insulin 
infusion include: 
• The fact that direct costs are greater.
• CSII therapy is labour-intensive for both providers 
and patients, or their caregivers.
• Since only short-acting insulin is used, accidental 
disconnection or malfunction of the infusion will 
cause insulin deficiency within minutes, together 
with the risk of ketoacidosis after several hours if 
suitable measures are not taken. This risk requires 
frequent blood glucose tests and attention to 
elevated test values.
• A risk of infection at the insertion site. However, this 
can be prevented by following aseptic insertion 
techniques, varying the insertion site every three 
days and applying an antibiotic ointment if 
necessary.
• Users have an external device attached to their 
body at all times.
Selection of healthcare providers
The concept of specialised and designated facilities 
for CSII is becoming an international norm and helps 
to ensure the best possible outcomes for patients 
and funders. Insulin pump therapy requires an above-
average level of diabetes management, more 
intensive patient education and training, and close 
follow-up. All of this needs to take place within a 
care framework that is suitably equipped to take the 
technological peculiarities of this form of treatment, its 
associated risks, the entailed change in lifestyle and 
its cost, into account. The establishment of a diabetes 
treatment facility conceived specifically to deal with 
patients who are treated by pumps is an ideal for 
which to strive. 
This requires a full multidisciplinary team, that at the 
very least, must include:
• A physician with a special interest in type 1 diabetes 
and insulin pump therapy.
• A diabetes nurse or educator with special training 
in CSII.
• A dietitian with special expertise in managing type 
1 diabetes. 
Team selection
Currently, there is no medical supervision or certifying 
process to regulate the use of this complex therapy. 
Any medical practitioner is free to prescribe CSII. The 
growth in the number of doctors wanting to prescribe 
CSII has been driven mainly by the manufacturers of 
CSII devices, and often patient support is provided 
only by employees of the manufacturer, a practice 
that should be discouraged. Both funders and patients 
receive no guidance with regard to provider expertise. 
At present, ACE-SA is unable to issue comprehensive 
guidance on the choice or accrediation of all medical 
practitioners who wish to provide CSII services. This 
stems from the fact that any practitioner may claim 
to have a special interest (without formal training) 
in type 1 diabetes and CSII, and it is not possible for 
ACE-SA to verify these individual claims. However, 
endocrinologists (paediatric and nonpaediatric), by 
the very nature of their training, are deemed to have 
the requisite knowledge and experience to manage 
type 1 diabetes and MDI. 
Therefore, ACE-SA recommends the following:
• All registered endocrinologists who have completed 
an ACE-SA-approved training course in CSII, should 
be considered to be preferred providers for the 
initiation and maintenance of pump therapy. 
• Training in the use of CSII should become available 
to endocrine registrars and fellows, either through 
access to a local CSII facility, or through the 
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establishment of CSII facilities and expertise 
within training hospitals, so that graduating 
endocrinologists will automatically qualify to initiate 
pump therapy in the future. 
• Practitioners who are considered to be 
diabetologists by their peers, and who are referred 
patients by their colleagues for CSII, should also be 
considered as preferred providers for CSII therapy, 
provided that they have completed an ACE-SA-
approved training course in CSII. For the purposes 
of this document, a diabetologist is defined as 
a medical practitioner whose workload involves 
managing diabetes mellitus > 80% of the time. 
• ACE-SA recommends that for non-endocrinologists 
and non-diabetologists wishing to undertake CSII 
therapy, the funders of health care (public and 
private) will need to establish managed-care 
programmes in conjuction with known experts in this 
field, in order to facilitate a wider preferred provider 
network for CSII, if this is deemed necessary. 
•	 Educator	 and	 dietitian	 selection:	Members of the 
Diabetes Education Society of South Africa (DESSA) 
and dietitians wanting to manage insulin pump 
therapy must first be experienced in managing 
type 1 diabetes.Then, they will  also need to acquire 
the additional skills necessary for managing CSII 
patients. It is hoped that DESSA will establish a 
formal training course for this purpose. Dietitians 
must also posess additional expertise in educating 
patients on carbohydrate counting. Educators and 
dietitians are also required to attend at least one 
ACE-SA-approved CSII course.
• All members of the specialist team should engage 
in continuing medical education activity relating to 
CSII annually.
• The initiation and maintenance of insulin pump 
therapy by industry representatives is no longer 
an acceptable practice. However, industry 
representatives may only participate in device 
training and troubleshooting prior to, or during, 
the initiation process. They are not permitted to 
participate in insulin dose setting or adjusting.
The responsibilities of the healthcare team will include:
• The provision of an environment and facility that is 
fully capable of training and educating the patient 
(and family) in pump usage.
• The provision of a 24-hour emergency number or 
“hotline” staffed by someone who understands 
pump therapy, and who can provide medical and 
technical counselling 24 hours a day throughout 
the year.
• Having access to and knowledge of continuous 
glucose monitoring systems.
• Getting informed consent from patients to enter 
their demographic, clinical, laboratory and self-
blood glucose monitoring data into a national CSII 
register.
Patient selection
The following is very important:
Insulin pump therapy should not be considered as “an 
easy way out” for patients who are nonadherent to their 
treatment regimens, who do not wish to perform self –
blood glucose monitoring, or who are seeking an “easy” 
alternative to multiple injections. Rather, CSII should be 
reserved for those patients who are concerned about 
their glycaemic control, who are extremely motivated 
and meticulous with their self-care, and who despite 
this, fulfil the criteria outlined below. The healthcare 
provider should not automatically consider or prescribe 
CSII because a patient or parent requests it, or because 
glucose control is not optimal. Pump therapy should be 
primarily reserved for patients with specific problems 
which may include the wish to achieve the quality-of-
life benefits of insulin pump therapy. Patients should be 
under the management of a specialist care team, as 
outlined in the previous section. 
Patients who may be considered for insulin infusion 
pump therapy
Before patients can be considered for CSII therapy, 
they must:
• Have demonstrated knowledge of and adherence 
to MDIs with appropriate dose adjustments.
• Have demonstrated the willingness to perform 
home blood glucose monitoring at least four times 
daily, and preferably six times a day.
• Have shown, to the satisfaction of the healthcare 
team, that they do not regularly miss injections or 
abuse their meal plan, and are willing to work with 
the multidisciplinary team.
• Have been instructed on carbohydrate counting 
by a qualified dietitian.
• Be motivated to succeed and have realistic 
expectations.
• Ideally, patients should be required to enter into 
a contract with the pump centre for pre-pump 
appraisal, education and ongoing management. 
Explicit in this contract will be indications for insulin 
pump therapy, pre-determined follow-up with the 
insulin pump team, and a definition of treatment 
targets to be maintained.
• Have none of the contraindications outlined below.
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Patients and/or family members must:
• Understand the factors influencing blood glucose 
levels and have the ability to vary and plan bolus 
doses based on tested blood glucose levels, 
planned carbohydrate consumption during the 
next meal, and planned physical exercise.
• Feel comfortable with the pump and have the 
ability to operate it.
• Preferably, have a family support system, as 
well as the support of a healthcare team who is 
knowledgeable in pump use and who is available 
24 hours a day.
• Have experience in intensive therapy with multiple 
injections.
• Be willing to sign a contract agreeing on patient-
specific outcome goals and minimum required 
annual follow-up visits.
• Undergo an appropriate training and education 
programme in pump use.
Children must have access to an adult during school 
hours in case of pump problems, and the ability to 
programme the bolus dose at school.
Indications for initiating treatment with 
continuous subcutaneous insulin infusion 
Metabolic 
The “difficult to stabilise” patient with diabetes is the 
favoured indication for pump therapy. 
Pump therapy should be considered for these patients, 
particularly in the following circumstances:
• Frequent severe hypoglycaemic episodes, despite 
a careful management review by an expert team.
• Hypoglycaemia unawareness, or recurrent severe 
hypoglycaemic episodes, which persist after a 
trial of therapy with a long-acting insulin analogue 
(Lantus® or Levemir®).
• Case-by-case consideration given to patients 
with extremely poor control and recurrent hospital 
admissions.
• Infants, toddlers and children with diabetes, in 
whom metabolic control is difficult to achieve using 
MDIs because of enhanced insulin sensitivity, erratic 
dietary patterns and logistical issues that relate to 
insulin delivery.
• Selected patients with anorexia nervosa and 
bulimia nervosa.
• Patients who are on MDIs, following a prescribed 
meal plan, testing blood glucose levels four or more 
times per day, and who are still not achieving their 
target haemoglobin A1c (HbA1c).
• Poor control, resulting from severe needle phobia.
Lifestyle
Pump therapy is suitable for patients with diabetes 
who have irregular eating, working and resting 
times, e.g. those who work shifts, travel frequently or 
engage in physically demanding sporting activities. 
Pump treatment enables these patients to achieve 
satisfactory blood glucose targets, which is difficult to 
achieve with conventional MDI regimens. It allows for 
fewer constraints on timetabling and making up meals.
This includes patients with type 1 diabetes who are 
well controlled using MDIs, but who seek the improved 
quality of life that is on offer through CSII use.
Pregnancy
Insulin pump therapy may be proposed to achieve 
excellent control of diabetes before conception and 
during pregnancy. It may also be started early in 
pregnancy for the rapid improvement of glycaemic 
control.
Prospective patients who meet the selection criteria 
and indications for CSII should be referred to a local 
expert pump team for evaluation, initiation and 
ongoing management of insulin pump therapy, should 
it be deemed appropriate by the full multidisciplinary 
team who is trained in pump therapy.
Contraindications for initiation or ongoing 
treatment with continuous subcutaneous insulin 
infusion
Treatment by pump can be dangerous because of the 
risk of rapid development of ketoacidosis if the infusion 
is stopped. Therefore, it is contraindicated in patients 
who do not monitor themselves with regular home 
blood glucose monitoring, or who are not capable of 
troubleshooting insulin pump problems. 
The following are absolute contraindications to pump 
therapy:
• Patients who are poorly committed to pump 
therapy.
• Patients with a pattern of nonadherence to the 
recommendations of the managing centre.
• Patients on CSII, who over a period of six months to 
a year, fail to achieve or maintain improved blood 
sugar control (improved HbA1c and/or a reduction 
in hypoglycaemia) when this was the primary 
indication for initiation of CSII therapy.
• At present, there is insufficient evidence to 
recommend CSII for patients with type 2 diabetes.
Choice of insulin and pump device
The recommended insulin for pump use is a rapid-
acting insulin analogue, e.g. Humalog®, NovoRapid® or 
Apidra®. 
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The choice of insulin pump should be at the discretion 
of the doctor and the patient. Device-specific factors 




• Ease of programmability.
• Computer software and download and upload 
capabilities.
• Minimum-dose adjustment increment for basal and 
bolus rates.
• Water-tightness.
• Compatibility with glucose monitoring devices.
• Cost of device and consumables.
• Device support from the manufacturer.
The recommendations presented herein are not meant 
to replace the judgement and discretion of physicians 
who treat individual patients, but rather to formulate 
guidelines to facilitate their work. This guideline will be 
reviewed every two years, or sooner, if necessary.
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